TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Clinical trial NCT04129502 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04129502
- Sponsor
- Takeda
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-10
- Primary completion
- 2026-10-31
- Enrollment
- 354
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.